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Abstract 
 
Background: Depressive symptoms among patients with amyotrophic lateral sclerosis (ALS) 
are usually measured with conventional questionnaires. These measurements do not consider 
the specific circumstances of the underlying disease. The purpose of this study was to assess 
the validity of a new short 12 items ALS-Depression-Inventory (ADI-12). We determined 
convergent, criterion, and concurrent validity. The Structured Clinical Interview (SCID) for 
DSM-IV was used as the gold standard and the Beck Depression Inventory (BDI) and the 
WHO Well Being Index (WHO-5) to assess concurrent validity. Methods: A total of 39 ALS 
patients in all stages of the disease were interviewed. Convergent validity was estimated by 
the inter-correlation between the ADI-12 and the BDI. Criterion and concurrent validity were 
specified with respect to sensitivity, specificity and predictive values. Receiver Operating 
Characteristics (ROC) and Areas Under the Curves (AUC) were calculated. Results: All three 
depression scales showed excellent internal consistencies (Cronbach’s α: 0.8-0.9). The 
correlation between the ADI-12 and the BDI was high (r = .80). For the ADI-12 a cut-off of ≥ 
30 (SE = 100%, SP = 83%) identified all patients with a current episode of major depression. 
A more liberal cut-off (≥ 23) identified all patients with any depressive disorder including 
minor depression at the cost of specificity (60%). Conclusions: With the ADI-12 ALS-
patients with depressive disorders can be reliably identified. We recommend the ADI-12 for 
routine screening in primary care of ALS patients.  
 
Key words: amyotrophic lateral sclerosis, depression, ALS-Depression-Inventory, screening, 
validity. 
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Introduction 
 
Amyotrophic lateral sclerosis (ALS) is a fatal progressive motor neuron disease, which causes 
proceeding weakness of limbs and bulbar muscles. Its etiology is not yet fully understood and 
no curative therapy is available. In late stages of the disease, progressing paralysis can result 
in the so called locked-in state in which only residual muscular movement is possible 
(Borasio et al., 1998; Norris, 1992). Depression is associated with survival in ALS patients 
and therefore is a key factor to be identified (McDonald et al., 1994; Paillisse et al., 2005).  
 
Comparing depression rates reported in the literature is difficult because different instruments 
have been used.  The vast majority of studies relied on self-report questionnaires, such as the 
BDI (Beck et al., 1961). These studies reported depression rates ranging from 4% to 44% 
(Hogg et al., 1994; Houpt et al., 1977; Kübler et al., 2005a, Kübler et al., 2005b; Lou et al., 
2003; Massman et al., 1996; Moore et al., 1998, Moore et al., 1997; Rabkin et al., 2005, 
Rabkin et al., 2000; Tedman et al., 1997; Trail et al., 2003). However, questionnaires provide 
information about the severity of depressive symptoms after a diagnosis has been made but do 
not allow us a formal diagnosis. Studies on depression using diagnostic interviews according 
to the DSM-IV (American Psychiatric Association, 2000) delivered highly consistent rates of 
Major Depression Disorder (MDD) of 9 to 11% among ALS patients (Ganzini et al., 1999; 
Rabkin et al., 2000).  
 
Kübler and colleagues developed the ADI-12 to improve the detection of depressive 
symptoms in patients with neurodegenerative diseases (Kübler et al., 2005a). The ADI-12 is a 
short self-report screening questionnaire consisting of 12 items (Table 1). None of the items 
refer to somatic or motor-related symptoms taking into account the progressive physical 
impairment which may culminate in severe motor paralysis and life sustaining treatment. The 
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ADI-12 assesses a homogeneous, one-dimensional construct that is described as “mood, 
anhedonia and energy” (Kübler et al., 2005a). We designed this study to reappraise the 
validity of the ADI-12 as a screening instrument for depressive disorders in a two-stage 
diagnostic process.  
 
ALS-Depression-Inventory (ADI-12) 
This questionnaire consists of 12 statements with 4 possible answers: 'I fully agree, 'I agree', 
'I don't agree' and I do not agree at all'. Please read every statement precisely and think about 
to what extent the statement is applicable to you in the last two weeks including today. Please 
mark (tick) the right answer for you. Please cross only one answer at a time and do not leave 
any statements open. 
 
  I fully 
agree 
I agree I don't agree I do not 
agree at all 
1 I am happy and I smile often. 
 
        
2 I can appreciate life despite my 
circumstances. 
 
        
3 I can get away from it all and I am 
often relaxed. 
 
        
4 I feel alive and vital. 
 
        
5 More often than not I am sad  
        
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6 I have lost all interest in family and 
friends. 
 
        
7 Most often I feel empty. 
 
        
8 There is nothing that I look forward 
to or that I can enjoy. 
 
        
9 I often feel lost and abandoned and 
don’t know how to carry on  
        
10 I look forward to every new day. 
 
        
11 I often wish I were dead. 
 
        
12 I feel like I have lost all of my 
energy. 
 
        
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Methods 
 
Participants 
A total of 66 ALS patients were invited to participate in the study approved by the Ethical 
Review Board of the Medical Faculty, University of Tübingen. All patients had regular 
contact to either the outpatient ALS clinic of the Department of Neurology at the University 
of Ulm, the Marienhospital in Stuttgart, the ALS outpatient clinic or the Institute of Medical 
Psychology and Behavioural Neurobiology, University of Tübingen. Forty-one patients gave 
informed consent of which 39 were interviewed (mean age [SD]: 57.62 [±8.86], range 37-72; 
19 men). Two patients had to be excluded from analyses because their communication code 
via eye blinks was too ambiguous. Mean ALSfRS score was 19.90 [±12.14, range 0-39]. 
Mean time since ALS diagnosis was 43.87 months [±37.46, range 1-170].  
 
Instruments 
ALS Functional Rating Scale: To determine the degree of physical impairment, we used the 
ALSfRS (Group ACTSAPI-IS, 1996), a scale that includes 10 items that have to be rated 
from 4 (best possible) to 0 (worst possible). Results can range from 0 (locked-in) to 40 (no 
impairment). 
 
ALS-Depression-Inventory: The ADI-12 (Kübler et al., 2005a) required patients to estimate 
how much they agree with each statement on a 4-point Likert-type scale with respect to the 
last 2 weeks. Scores range from ‘0’ (best possible) to ‘48’ (worst possible) with scores 
between 22 and 28 indicating mild depression and those above 28 clinically relevant 
symptoms (Kübler et al., 2005a). 
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Beck Depression Inventory: The BDI (Beck et al., 1961; Hautzinger et al., 1994) is a well-
established questionnaire for assessing the severity of depression. Although not intended by 
the authors, the BDI is frequently used as screening instrument, also in ALS patients. 
 
WHO Well-Being-Index: The WHO-5 (World Health Organization, 1998) includes 5 items, 
which are not specific for depression, but are designed to measure psychological well-being. 
The score ranges from zero (worst possible) to 25 (best possible), a score under 14 is regarded 
to require further investigation (Hautzinger and Meyer, 2002; World Health Organization, 
1998). 
 
Structured Clinical Interview DSM-IV (SCID): For diagnosing MDD and any other depressive 
disorder we used section A (affective disorders, current and lifetime) of the SCID (Spitzer et 
al., 1996; Wittchen et al., 1997) which was regarded as ‘gold standard’. Interviews were 
conducted by two clinical psychologists who underwent extensive interviewer training. All 
interviews were videotaped and supervised by an expert (TDM). 
 
Procedures 
All patients were interviewed at home. Data collection lasted from 1.5 to 3 hours depending 
on the communication abilities of the patient. 
 
Statistical Analysis 
Internal consistencies were calculated for the screening-instruments. Sensitivity (SE), 
specificity (SP), positive predictive values (PPV) and negative predictive values (NPV) were 
determined for a SCID-diagnosis of MDD and “any depressive disorder”. Following Löwe 
and colleagues optimal cut-offs were determined (Löwe et al., 2004). In a two-stage 
diagnostic process, they proposed a maximal SE and a corresponding SP of at least 75%. To 
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identify optimal cut-off points, we plotted Receiver Operating Characteristics (ROC). A 
measure for the tests´ overall accuracy is the ‘Area Under the Curve’ (AUC). To examine 
whether the ADI-12 was superior to the ALS-unspecific questionnaires, we compared SE and 
SP for all questionnaires using Cochran´s Q and chi-squared-tests (Chochinov et al., 1997; 
Henkel et al., 2004). We also compared the AUCs via visual inspection without conducting 
statistical comparisons. Statistical significance was set at alpha = .05, and all tests were two-
tailed.  
 9
Results 
 
The mean ADI-12 score was 23.85 [±7.13, range 12-42]. Using the thresholds suggested by 
Kübler and colleagues (2005a), 38.5% of the patients had no symptoms, 33.3% mild 
depressive symptoms, and 28% clinically relevant symptoms. Mean score of the BDI was 
14.67 [±7.13, range 1-31] and of the WHO-5 14.10 [±5.89, range 2-22]. Cronbach´s Alpha for 
the ADI-12 was .91, for the BDI .80, and for the WHO-5 .88.  
 
SCID results identified the majority of the ALS patients as free of a current episode of MDD. 
Four patients (10%) were diagnosed with current MDD, one with dysthymia, and two with 
minor depression, which is defined as a mood disturbance of at least 2 weeks´ duration, with 
between 2 and 5 symptoms. Ten patients (25.6%) had “lifetime” depressive episodes; two 
patients were classified as MDD partial remission.  
 
Pearson correlation between ADI-12 and BDI was r = .81 (p < .01), indicating that the two 
scales measured closely related constructs. The correlation between ADI-12 and WHO-5 was 
lower, but also significant (r = -.64; p < .01).  
 
Criterion and concurrent validity were assessed separately for two diagnostic groups: “Major 
Depressive Disorder” (MDD), including patients with a current episode of major depression, 
and “any depressive disorder”, including all depressed patients (n = 9).  
 
Analysis for MDD: The operating characteristics of the three screening tools with respect to 
standard cut-offs and a new optimal cut-off for our sample of ALS patients are shown in 
Table 1a. For the standard cut-offs, all three measures showed maximal SE. The ADI-12 and 
the BDI also reached a SP above 75%. If we used optimal cut-offs, all three measures met the 
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demands of a two-stage screening. For the ADI-12, we identified an optimal cut-off of > 30 
with maximum SE of 100% and SP of 83%. We could not find significant differences 
between the instruments. The screening accuracy of the three instruments for all possible cut-
offs is depicted in the ROCs (Table 1b). The ROCs as well as the AUC values of .90, .94, and 
.91 showed that all three instruments discriminated between ALS patients with MDD and 
without MDD.  
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Table 1a: Operating characteristics of the ADI-12, BDI, and WHO-5 for MDD (n = 4). 
cut-off SE, %  
(95% CI) 
SP, %  
(95% CI) 
PPW, % 
 (95% CI) 
NPW, %  
(95% CI) 
AUC 
(95% CI) 
ADI-12  
standard¹ 
 
optimal² 
≥ 22 
≥ 29 
≥ 30 
100 (40-100) 
100 (40-100) 
100 (40-100) 
43 (27-60) 
80 (63-91) 
83 (66-93) 
17 (6-38) 
36 (12-68) 
40 (14-73) 
100 (75-100) 
100 (85-100) 
100 (85-100) 
.90* 
(.80 – 1.0) 
BDI 
standard¹ 
 
optimal² 
≥ 11 
≥ 18 
≥ 23 
100 (40-100) 
100 (40-100) 
100 (40-100) 
37 (22-55) 
74 (56-87) 
91 (76-98) 
15 (5-36) 
31 (10-61) 
57 (20-88) 
100 (72-100) 
100 (84-100) 
100 (87-100) 
.94** 
(.86 – 1.0) 
WHO-5 
standard¹ 
optimal² 
≤ 13 
≤ 8 
100 (40-100) 
100 (40-100) 
63 (45-78) 
83 (66-93) 
24 (8-50) 
40 (14-73) 
100 (82-100) 
100 (85-100) 
.91** 
(.82 – 1.0) 
 Standard cut-off¹ optimal cut-off ² 
SE ADI-12 = BDI = WHO-5 = 100 ADI-12 = BDI = WHO-5 = 100 
SP Q(2) = 9,33; p < .01 
ADI-12 versus BDI: p = .50 
ADI-12 versus WHO-5: p < .05 
BDI versus WHO-5: = .13 
Q(2) = 6,00; p = 0.05 
ADI-12 versus BDI: p = .25 
ADI-12 versus WHO-5: p = 1,00 
BDI versus WHO-5: p = .25 
¹Standard cut-offs recommended in literature for each screening instrument (Hautzinger et al., 
1994; Kübler et al., 2005a; World Health Organization, 1998) 
²Optimal cut-off recommended for a two-stage screening (maximal SE, and SP ≥ 75%) 
95% CI = 95% Confidence Interval; * = p ≤ 0.05; ** = p ≤ 0.01; Q= Cochran´s Q 
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Table 1b: MDD: ROC curves for the ADI-12, BDI, and WHO-5. The optimal cut-off points 
are represented by the trajectory of each curve that are highest and nearest to the top left 
angle. They fit the criteria of a two-stage screening (maximal SE, and SP ≥ 75%). The 
diagonal reference line represents the null hypothesis (AUC = 0.50). 
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Analysis for “any depressive disorder”: The correct classification of all depressed patients 
required a more liberal cut-off.  With the standard cut-off of ≤ 13 for the WHO-5 we could 
not identify all depressed patients (SE = 78%). None of the screenings reached a maximal SE 
of 100% when optimal cut-offs were used. The ADI-12 showed the highest value with nearly 
90%. The BDI and the WHO-5 achieved 78% respectively. With respect to SP the ADI-12 
showed the best result (87%). With an ADI-12 cut-off ≥ 23, all nine patients were correctly 
identified (SE = 100) at the cost of specificity (SP = 60%). However, the differences between 
these instruments were not significant (Table 2a). The ROCs of all three screenings showed 
the difficulties of a maximal SE and a simultaneous SP ≥ 75% (Table 2b).  
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Table 2a: Operating characteristics of the ADI-12, BDI, and WHO-5 for “any depressive 
disorder” (n = 9). 
cut-off SE, %  
(95% CI) 
SP, %  
(95% Ci) 
PPW, % 
 (95% CI) 
NPW, %  
(95% CI) 
AUC  
(95% CI) 
ADI-12 
standard¹ 
 
optimal² 
≥ 22 
≥ 29 
≥ 27 
100 (63-100) 
78 (40-96) 
89 (51-99) 
50 (32-68) 
87 (68-96) 
87 (68-96) 
38 (20-59) 
64 (32-88) 
67 (35-89) 
100 (75-100) 
93 (75-99) 
96 (79-100) 
.89*** 
(.79 – 1.0) 
 
BDI 
standard¹ 
 
optimal² 
≥ 11 
≥ 18 
≥ 18 
100 (63-100) 
78 (40-96) 
78 (40-96) 
43 (26-62) 
80 (61-92) 
80 (61-92) 
35 (18-56) 
54 (26-80) 
54 826-80) 
100 (72-100) 
92 (73-99) 
92 (73-99) 
.89*** 
(.79 – 1.0) 
WHO-5 
standard¹ 
optimal² 
≤ 13 
≤ 12 
78 (40-96) 
78 (40-96) 
667 (47-82) 
77 (57-89) 
41 (19-67) 
50 (24-76) 
91 (69-98) 
92 (72-99) 
.86** 
(.73 – 1.0) 
 standard cut-off¹ optimal cut-off ² 
SE ADI-12 = BDI = WHO-5  
 
Q(2) = 2,00; p = .368 
ADI-12 = BDI = WHO-5 
SP Q(2) = 9,33; p < .01 
ADI-12 versus BDI: p = 0.5 
ADI-12 versus WHO-5: p < .05 
BDI versus WHO-5: p = .125 
Q(2) = 4,67; p = .097 
ADI-12 = BDI = WHO-5 
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Table 2b: Any depressive disorder: ROC curves for the ADI-12, BDI, and WHO-5. The 
points at which these graphs approach a horizontal line lie far to the right of the ROC figure. 
This means that a maximal SE of 100% is only possible at the cost of SP. The diagonal 
reference line represents the null hypothesis (AUC = 0.50). 
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Discussion 
 
The purpose of this study was to examine the validity of the ADI-12 as a screening tool for 
depression in ALS patients. While ADI-12, BDI and WHO-5 demonstrated high reliability, 
especially ADI-12 and BDI, were highly correlated, indicating a high convergent validity of 
the ADI-12. 
 
Adopting a two-stage diagnostic approach, a screening for depression was followed by a 
structured clinical interview. Using the ADI-12 cut-off of 30 or higher, a maximum SE 
(100%) and an SP of 82% was achieved, meaning that all patients with MDD were identified. 
A cut-off ≥ 23 identified all patients with “any depressive disorder” at the cost of SP (60%), 
thus falling below the criterion recommended by Löwe and colleagues (Löwe et al., 2004).  
Contrary to our hypothesis instruments which do not take into account the specificities of the 
underlying motor neurone disease did not lead to more biases in detecting depression. 
Although characteristics of the ALS and items of those questionnaires are confounded, it 
seems that patients often discriminate between their ALS-related physical impairments and 
symptoms of depression. However, those items may elicit irritation in some patients. 
Therefore, although the ADI-12 and BDI seem to do equally well in detecting depression in 
ALS-patients, the advantage of the ADI-12 of being much shorter, less time consuming and 
inducing less irritation renders it the preferable instrument. In our sample the ALS patients 
preferred themselves the ADI-12, definitely.   
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Conclusions  
 
The broad range (0-44%) of “depression” in samples of ALS patients seems to be mainly due 
to the use of different instruments, including self-ratings. When standardised clinical 
interviews are used for diagnosis, the rate of depression (MDD) in ALS is about 10% 
(Ganzini et al., 1999; Rabkin et al., 2000), which was further confirmed by the presented 
study. Based on our data, we recommend the ADI-12 for routine screening in ALS patients, 
due to its shortness and high validity. We suggest a two-stage diagnostic process .Patients 
who have ADI-12 scores  ≥23 should be assessed more thoroughly. Normally indivduals with 
depression receive psychological and/or pharmacological treatment, but this is rarely the case 
for depressed ALS patients. No data on clinical trials exist and antidepressants are often 
prescribed in low dosages and are not monitored for effectiveness (Forshew and Bromberg, 
2003; Ganzini et al., 1999; Kurt et al., 2007). Taken together, treatment of depression in ALS 
has been neglected and needs further consideration.  
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